Table 2.
Carcinomas (non-colorectal) in which studies have found an association between tumor-infiltrating immune cells and prognosis
| Reference | Principal findings Correlation with better prognosis |
n | P value | Stage of carcinoma |
Methods | Definition of immune cells | Follow-up period (years) |
|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | |||||||
| 28 | Positive correlation for cytotoxic T-cells, negative for T-regs. |
302 | <0.001 | I-IV | H, IHC, TMA | CD3+, CD4+, CD8+, GrB+ and FoxP3+ tumor infiltrating cells. | >9 |
| 29 | Negative correlation for T-regs. | 147 | <0.01 | I-III | H, IHC | CD4+, CD8+, and FoxP3+ tumor infiltrating cells. | 4 |
| 30 | Positive correlation for DC and cytotoxic T-cells. |
123 | <0.01 | I-IV | H, IHC | CD3+, CD8+, CD45RO+ T-cells and S-100+ DC in HCC nodules. | 2 |
| 31 | Negative correlation for Th17-cells. | 178 | <0.001 | I-IV | IHC, FACS | CD3+, CD4+, IL-17A+, CD62L-, CD45RO+, CCR4+, and CCR6+cells. | 8 |
| Gallbladder carcinoma | |||||||
| 32 | Positive correlation for CD4+ and CD8+ T-cells and DC. |
110 | <0.01 | I-IV | H, IHC | CD4+, CD8+, CD57+, and S-100 protein+ tumor infiltrating cells. | >5 |
| Pancreatic carcinoma | |||||||
| 33 | Positive correlation for CD4+ and CD8+ T-cells. |
80 | <0.01 | I-IV | H, IHC | CD4+, CD8+, and S-100 protein+ tumor infiltrating cells. | 8 |
| 34 | Negative correlation for T-regs. | 198 | <0.001 | I-IV | H, IHC | CD4+, CD25+, and FoxP3+ tumor infiltrating cells. | 4 |
| Esophageal carcinoma | |||||||
| 35 | Positive correlation for CD4+ and CD8+ T-cells. |
70 | <0.001 | I-IV | H, IHC, RT-PCR | Tumor infiltrating, peritumoral or stromal CD8+, IFNg+ T-cells. | >6 |
| 36 | Positive correlation for CD4+ and CD8+ T-cells. |
122 | <0.0001 | I-IV | H, IHC | Tumor infiltrating CD4+, CD8+, and CD57+ cells. | >9 |
| Ovarian carcinoma | |||||||
| 37 | Positive correlation for T-cells. | 186 | <0.001 | III-IV | H, IHC, FACS, RT-PCR |
CD3+, CD4+, CD8+, CD16+, CD19+ and CD45+ cells. | >11 |
| 38 | Positive correlation for CD3+ T-cells. | 116 | <0.001 | I-IV | H, IHC | CD3+ T-cells in cancer stroma and epithelium. | 10 |
| 39 | Positive correlation for CD8+ T-cells and a high CD8+/T-reg ratio. |
117 | <0.001 | I-IV | H, IHC | CD4+, CD8+, CD25+, and FoxP3+ tumor infiltrating cells. | 10 |
| 40 | Positive correlation for Th17-cells. | 85 | <0.001 | II-IV | H, IHC, FACS | Tumor infiltrating CD3+, CD4+, CD45RO+, CCR4+, CCR6+, IL-17+ Th17-cells. |
4 |
| Endometrial carcinoma | |||||||
| 41 | Positive correlation for CD3+ T-cells. | 65 | <0.05 | I-IV | H, IHC | Tumor infiltrating CD3+, CD4+, CD8+, and CD57+ cells. | >10 |
| 42 | Positive correlation for CD8+ T-cells and a high CD8+/T-reg ratio. |
368 | <0.05 | I-IV | H, IHC, TMA | Tumor infiltrating CD8+, CD45RO+, and FoxP3+ cells. | >5 |
| Cervical carcinoma | |||||||
| 43 | Positive correlation for CD8+ T-cells, and a high CD8+/CD4+ or CD8+/T-reg ratio. |
59 | <0.05 | I-II | H, IHC | Tumor infiltrating CD1a+, CD3+, CD4+, CD8+, CD45RO+, CD57+, FoxP3+, and DC-Lamp+ cells. |
− |
| Bladder carcinoma | |||||||
| 44 | Positive correlation for tumor infiltrating lymphocytes. |
514 | <0.01 | I-IV | H, LM | Tumor infiltrating lymphocytes. | 15 |
| Urothelial carcinoma | |||||||
| 45 | Positive correlation for CD8+ T-cells. | 69 | <0.05 | I-IV | H, IHC | Tumor infiltrating CD8+ T-cells. | >8 |
DC: dendritic cells; FACS: flow cytometry; H: histopathological analysis; IHC: immunohistochemistry; LM: light microscopy; TMA: tissue microarray; T-regs: regulatory T-cells.